Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Manchester UK, 25th June 2013 -- F2G Ltd, a privately-held antifungal drug discovery and development company and The
University of Manchester, today announced the commencement of a 6.1 million euro
EU-funded project to discover and develop novel antifungal drugs to treat serious, lifethreatening
fungal infections. The NOFUN project is a collaborative project under the
7th Framework Program of the European Commission which brings together five
partners to accelerate the development of a number of F2G’s broad spectrum
About two million people die each year because of fungal infection and resistance is
rapidly emerging to the most common drugs used to treat these diseases. This project
aims to develop novel agents with completely new ways of acting in order to combat the
increasing tide of drug resistant fungal infections. NOFUN will use F2G’s discovery
assets and the University’s fungal genomics platforms in addition to the drug
development and characterisation expertise of the other partners.
Participants in the NOFUN Project are F2G Ltd (UK), The University of Manchester
(UK), Pharmacelsus GmbH (Germany), OncoTargeting AB (Sweden) and Universitat i
Rovira Virgili (Spain).
Dr Mike Birch of F2G and Scientific Coordinator of NOFUN added: “Competition for
funding in this call was immense and the NOFUN award represents a significant
validation of the project and the partners. F2G is delighted to lead the scientific program
to develop much needed new antifungal agents”.
Dr Mike Bromley, NOFUN Project Coordinator from The Manchester Fungal Infection
Group at The University of Manchester, said: “We are delighted that this project has
been funded and it confirms The University of Manchester as a centre of excellence in
fungal biology and disease. Hopefully this cash boost will help us to create new
treatments to tackle serious, life-threatening fungal infections.”
About F2G Ltd: Based in Manchester, UK, F2G Ltd is dedicated to the discovery and
development of new and clinically superior drug classes to treat life-threatening
systemic fungal infections in at-risk patient populations. This is a growing health risk for
which there are currently limited treatment options and for which demand is increasing
globally. Market growth is expected to increase with the emergence of new clinical
indications in allergies and asthma. For more information visit www.f2g.com
Help employers find you! Check out all the jobs and post your resume.